iBio, Inc. 8-K

What Happened
iBio, Inc. (IBIO) filed a Form 8-K on March 9, 2026, announcing preclinical body composition results from an obese non-human primate (NHP) study of IBIO-610, described as a potential first-in-class Activin E antibody candidate, and publishing an updated corporate presentation outlining strategic expansion into the cardiopulmonary space. The company said the small, not statistically powered study showed a fat-selective profile after two doses given once every eight weeks.

Key Details

• Study results (obese NHPs): IBIO-610 reduced visceral fat by 6.7% and total fat mass by 5.2% after two once-every-eight-week dosings; lean mass showed only a slight increase.
• Study context: Results come from a small preclinical NHP study and were not statistically powered. Company notes effects are consistent with other Activin E–targeting approaches seen in rodents and human trials.
• Strategic update: iBio updated its corporate presentation to describe expansion into the cardiopulmonary area, specifically pursuing PH-HFpEF (pulmonary hypertension with heart failure with preserved ejection fraction) using a myostatin x Activin A bispecific antibody program.
• Filing items: Disclosure furnished under Regulation FD (Item 7.01) and reported as Other Events (Item 8.01) in the 8-K dated March 9, 2026.

Why It Matters
For investors, the filing provides early preclinical evidence that IBIO-610 may selectively reduce fat—an effect aligned with Activin E pathway biology—but the study’s small size and lack of statistical powering limit conclusions about efficacy or clinical promise. The updated corporate presentation signals a strategic shift or expansion into cardiopulmonary disease (PH-HFpEF) and highlights a separate bispecific antibody program, which could broaden iBio’s development pipeline and potential future indications.